Study the Effect of Anastrozole on Estradiol and Cytochrome P450 (Aromatase Enzyme) in Postmenopausal Breast Cancer Patients

Abstract

In this study sixty patients were selected according to a positive estrogen receptor. All of 60 naturally or surgically postmenopausal women that had a diagnosis of breast cancer verified by histology breast cancer. Subdivided to with hormone treatment or without any treatment, Forty patients (group P1) with the ages range from 46 to 75 years, and were being treated with an aromatase inhibitor, Arimidex (1 mg) once daily, and another twenty (group P2) as newly diagnosed of breast cancer with ages ranging from 47 to 75 years. While the age of control ranging from (48-75) years old, used as a reference. Recent investigations have challenged the hypothesis that aromatization of androgens into estrogen is the sole production pathway for estrogens in postmenopausal women. The finding that estradiol persists in the plasma of patients receiving anastrozole treatment despite a near total inhibition of the aromatase enzyme suggests that alternative pathways for estrogen synthesis exist, which appeared in our results, aromatase and estradiol with treatment (452.34pg/ml) and (13.09pg/ml) respectively. An although evidence a positive and strong correlation between aromatase enzyme and estradiol (r=0.573, P=0.00).

Cytotoxicity anticancer activities of anastrozole against breast, liver hepatocellular, and prostate cancer cells

“…Recently, we reported the effect of anastrozole levels on estradiol in women with postmenopausal breast cancer. Strong positive correlations were found between serum aromatase and estradiol (r = 0.79-0.82) 18. We have also investigated the effect of aryl phosphonate derivatives on human breast cancer cells (MCF7) and liver carcinoma cell line (HepG2) 19.…”

“…Strong positive correlations were found between serum aromatase and estradiol (r = 0.79-0.82). 18 We have also investigated the effect of aryl phosphonate derivatives on human breast cancer cells (MCF7) and liver carcinoma cell line (HepG2). 19 The MCF7 cancer cell line is a very sensitive to estrogen receptor and can be used as a model to investigate the response of the hormone.…”

Leukemia Morbidity and Mortality among Children Admitted to Hiwa Hospital from January 2015 to January 2022: A Retrospective Study

“…However, another study in Diyala, Iraq, approved that childhood leukemia rate was directly related to age, gender, and blood group, with most recorded cases recorded in the age group 1-5 years. Additionally, it was indicated that blood group O and RhD positive are risk factors for the incidence of ALL in children, and group AB and RhD negative children seemed to be less susceptible [24]. Furthermore, it was found that 36% of the patients had an A+ blood group, followed by O+ (34.6%), and the minority was an AB-(0.5%).…”

Genetic Polymorphisms of the Efflux Transporter Gene ABCB1 and Their Effects on the Anastrozole Response in Iraqi Breast Cancer Patients

“…These studies suggest that estrogen is a mammary gland carcinogen (15) . Therefore, the use of aromatase inhibitors is a common strategy to treat women with hormone receptor-positive breast cancer (16) . Although anastrozole was used as an aromatase inhibitor, this study found a detectable quantity of E2 in the serum of breast cancer patients that was still within normal limits (Table 3), which suggests that there may be other pathways for estrogen synthesis.…”